Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Butterfly Network, Inc. or Haemonetics Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Butterfly Network, Inc. and Haemonetics Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Butterfly Network, Inc. and Haemonetics Corporation

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user’s smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Latest Health Care Equipment & Supplies and Butterfly Network, Inc., Haemonetics Corporation Stock News

As of June 18, 2026, Butterfly Network, Inc. had a $2.3 billion market capitalization, compared to the Health Care Equipment & Supplies median of $351.8 million. Butterfly Network, Inc.’s stock is NA in 2026, NA in the previous five trading days and up 304.55% in the past year.

Currently, Butterfly Network, Inc. does not have a price-earnings ratio. Butterfly Network, Inc.’s trailing 12-month revenue is $102.9 million with a -73.6% net profit margin. Year-over-year quarterly sales growth most recently was 25.0%. Analysts expect adjusted earnings to reach $-0.128 per share for the current fiscal year. Butterfly Network, Inc. does not currently pay a dividend.

Currently, Haemonetics Corporation’s price-earnings ratio is 36.2. Haemonetics Corporation’s trailing 12-month revenue is $1.3 billion with a 7.3% net profit margin. Year-over-year quarterly sales growth most recently was 4.8%. Analysts expect adjusted earnings to reach $5.219 per share for the current fiscal year. Haemonetics Corporation does not currently pay a dividend.

How We Compare Butterfly Network, Inc. and Haemonetics Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Butterfly Network, Inc. and Haemonetics Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Butterfly Network, Inc. and Haemonetics Corporation Stock Value Grades

Company	Ticker	Value
Butterfly Network, Inc.	BFLY	F
Haemonetics Corporation	HAE	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Butterfly Network, Inc. has a Value Score of 4, which is Ultra Expensive. Haemonetics Corporation has a Value Score of 43, which is Average.

The Value Stock Winner: No Clear Winner

Neither Butterfly Network, Inc. or Haemonetics Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Butterfly Network, Inc. or Haemonetics Corporation is the better investment when it comes to value.

Butterfly Network, Inc. and Haemonetics Corporation Growth Grades

Company	Ticker	Growth
Butterfly Network, Inc.	BFLY	D
Haemonetics Corporation	HAE	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Butterfly Network, Inc. has a Growth Score of 38, which is Weak. Haemonetics Corporation has a Growth Score of 95, which is Very Strong.

The Growth Grade Winner: Haemonetics Corporation

As you can clearly see from the Growth Grade breakdown above, Haemonetics Corporation has a more attractive growth grade than Butterfly Network, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Haemonetics Corporation could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Butterfly Network, Inc. and Haemonetics Corporation’s Momentum Grades

Company	Ticker	Momentum
Butterfly Network, Inc.	BFLY	A
Haemonetics Corporation	HAE	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Butterfly Network, Inc. has a Momentum Score of 97, which is Very Strong. Haemonetics Corporation has a Momentum Score of 68, which is Strong.

The Momentum Grade Winner: Butterfly Network, Inc.

As you can clearly see from the Momentum Grade breakdown above, Butterfly Network, Inc. is considered to have stronger momentum compared to Haemonetics Corporation. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Butterfly Network, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Butterfly Network, Inc. and Haemonetics Corporation Grades

In addition to Momentum, Value and Growth, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Butterfly Network, Inc. and Haemonetics Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Butterfly Network, Inc. or Haemonetics Corporation Stock?

Overall, Butterfly Network, Inc. stock has a Value Score of 4, Growth Score of 38 and Momentum Score of 97.

Haemonetics Corporation stock has a Value Score of 43, Growth Score of 95 and Momentum Score of 68.

Comparing Butterfly Network, Inc. and Haemonetics Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.